New antibacterial for conjunctivitis

Moxivig (moxifloxacin) eye drops are a new option for the treatment of purulent bacterial conjunctivitis.

Moxifloxacin is a fourth-generation fluoroquinolone antibiotic. It inhibits enzymes required for bacterial DNA replication, repair and recombination.1

In vitro tests were carried out to compare the activity of moxifloxacin, gatifloxacin, levofloxacin, ofloxacin and ciprofloxacin against 93 bacterial endophthalmitis isolates. Moxifloxacin was the most potent agent against Gram positive bacteria (p=0.05). It had equivalent potency to ciprofloxacin, gatifloxacin and levofloxacin against Gram negative bacteria.2

Commonly susceptible organisms include Corynebacterium species (including Corynebacterium diphtheriae), Staphylococcus aureus, Streptococcus species (including pneumoniae, pyogenes and viridans group), Enterobacter cloacae, Haemophilus influenza, Klebsiella oxytoca, Moraxella catarrhalis, Serratia marcescens, Propionibacterium acnes and Chlamydia trachomatis.

Cross-resistance of moxifloxacin with beta-lactams, macrolides and aminoglycosides is not expected. However, cross-resistance with other fluoroquinolones has been observed.3 Moxivig should not be used for the prophylaxis or empiric treatment of gonococcal conjunctivitis, because of the prevalence of fluoroquinolone-resistant Neisseria gonorrhoeae.1

View Moxivig drug record


  1. Moxivig Summary of Product Characteristics, March 2010.
  2. Mather R et al. Am J Ophthalmol 2002; 133: 463-6.
  3. Miller D. Clin Ophthalmol 2008; 2: 77–91.

Further information: Alcon

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more